ArticleBlood2016
Inducible epithelial resistance protects mice against leukemia-associated pneumonia.
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival.JCI insight · 2024Article
- Epithelial STAT3: A New Twist in Inducible Antimicrobial Resistance.American journal of respiratory cell and molecular biology · 2023Article
- Redox-Dependent Activation of Lung Epithelial STAT3 Is Required for Inducible Protection against Bacterial Pneumonia.American journal of respiratory cell and molecular biology · 2023Article
- Toll-like receptors 2, 4, and 9 modulate promoting effect of COPD-like airway inflammation on K-ras-driven lung cancer through activation of the MyD88/NF-ĸB pathway in the airway epithelium.Frontiers in immunology · 2023Article
- Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.Frontiers in immunology · 2022Review
- Host-directed therapy in foals can enhance functional innate immunity and reduce severity of Rhodococcus equi pneumonia.Scientific reports · 2021Article
- Immune Modulation to Improve Survival of Viral Pneumonia in Mice.American journal of respiratory cell and molecular biology · 2020Article
- Inducible epithelial resistance against acute Sendai virus infection prevents chronic asthma-like lung disease in mice.British journal of pharmacology · 2020Article
- Bronchial Epithelial Cells on the Front Line to Fight Lung Infection-CausingFrontiers in immunology · 2020Review
- Host defense mechanisms against Aspergillus fumigatus lung colonization and invasion.Current opinion in microbiology · 2019Review
- Pattern recognition receptors in fungal immunity.Seminars in cell & developmental biology · 2019Review
- Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against bacterial infections.PloS one · 2019Article
- Integrative Physiology of Pneumonia.Physiological reviews · 2018Review
- Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.European journal of pharmacology · 2018Article
- Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense.Mucosal immunology · 2018Review
- Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation.Clinics in chest medicine · 2017Review
- Immune responses to invasive aspergillosis: new understanding and therapeutic opportunities.Current opinion in infectious diseases · 2017Review
- Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.Clinics in chest medicine · 2017Review
- Pathogenesis of severe pneumonia: advances and knowledge gaps.Current opinion in pulmonary medicine · 2017Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Despite widespread infection prevention efforts, pneumonia remains the leading cause of death among patients with acute leukemia, due to complex disease- and treatment-dependent immune defects. We have reported that a single inhaled treatment with a synergistic combination of Toll-like receptor 2/6 (TLR 2/6) and TLR9 agonists (Pam2-ODN) induces protective mucosal defenses in mice against a broad range of pathogens. As Pam2-ODN-induced protection persists despite depletion of several leukocyte populations, we tested whether it could prevent pneumonia in a mouse model of acute myeloid leukemia (AML) remission induction therapy. Pam2-ODN prevented death due to pneumonia caused by Pseudomonas aeruginosa, Streptococcus pneumoniae, and Aspergillus fumigatus when mice were heavily engrafted with leukemia cells, had severe chemotherapy-induced neutropenia or both. Pam2-ODN also extended survival of pneumonia in NSG mice engrafted with primary human AML cells. Protection was associated with rapid pathogen killing in the lungs at the time of infection and with reduced pathogen burdens at distant sites at the end of observation. Pathogen killing was inducible directly from isolated lung epithelial cells and was not abrogated by the presence of leukemia cells or cytotoxic agents. Pam2-ODN had no discernible effect on replication rate, total tumor population, or killing by chemotherapy of mouse or human leukemia cells, either in vitro or in vivo. Taken together, we report that therapeutic stimulation of lung epithelial defenses robustly protects against otherwise lethal pneumonias despite the profound immune dysfunction associated with acute leukemia and its treatment. These findings may suggest an opportunity to protect this population during periods of peak vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.